Assyro AI

Orange Book product · Brand (NDA)

VANRAFIA

ATRASENTAN HYDROCHLORIDE

Brand (NDA)NDA 219208RX NOVARTIS

At a glance

Apr 02, 2025

Approved

Brand (NDA)

Application

Not listed

TE code

10

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 02, 2025

    1 yr 3 mo ago

  2. Today

  3. Patent 8623819 expires

    Listed method-of-use patent (U-3980) expiration.

    Aug 22, 2028

    in 2 yr 3 mo

  4. Exclusivity ends · NCE

    New chemical entity exclusivity (5 years)

    Apr 02, 2030

    in 3 yr 10 mo

  5. Patent 11874283 expires

    Listed method-of-use patent (U-3980) expiration.

    Feb 18, 2032

    in 5 yr 9 mo

  6. Patent 10016393 expires

    Listed drug product patent expiration.

    Jul 07, 2034

    in 8 yr 2 mo

  7. Patent 9364458 expires

    Listed drug product patent expiration.

    Jul 07, 2034

    in 8 yr 2 mo

  8. Patent 11491137 expires

    Listed method-of-use patent (U-3980) expiration.

    Dec 16, 2040

    in 14 yr 8 mo

  9. Patent 11998526 expires

    Listed method-of-use patent (U-3980) expiration.

    Dec 16, 2040

    in 14 yr 8 mo

  10. Patent 12121509 expires

    Listed method-of-use patent (U-3980) expiration.

    Dec 16, 2040

    in 14 yr 8 mo

  11. Patent 12370174 expires

    Listed method-of-use patent (U-3980) expiration.

    Dec 16, 2040

    in 14 yr 8 mo

  12. Patent 12521369 expires

    Listed method-of-use patent (U-3980) expiration.

    Feb 23, 2041

    in 14 yr 11 mo

  13. Patent 12582631 expires

    Listed method-of-use patent (U-3980) expiration.

    Mar 25, 2043

    in 17 yr

Pharmaceutical detail

Active ingredient

ATRASENTAN HYDROCHLORIDE

Strength

EQ 0.75MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 219208

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • NCENew chemical entity exclusivity (5 years)

    Apr 02, 2030

    in 3 yr 10 mo

Listed patents (10)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8623819Aug 22, 2028in 2 yr 3 mo
U-3980
11874283Feb 18, 2032in 5 yr 9 mo
U-3980
10016393Jul 07, 2034in 8 yr 2 mo
Product
9364458Jul 07, 2034in 8 yr 2 mo
ProductU-3980
11491137Dec 16, 2040in 14 yr 8 mo
U-3980
11998526Dec 16, 2040in 14 yr 8 mo
U-3980
12121509Dec 16, 2040in 14 yr 8 mo
U-3980
12370174Dec 16, 2040in 14 yr 8 mo
U-3980
12521369Feb 23, 2041in 14 yr 11 mo
U-3980
12582631Mar 25, 2043in 17 yr
U-3980
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.